Jean-Damien Charrier

USPTO Granted Patents = 140 (Patent Applications = 10)

CIPO Patents = 9 (Patent Applications = 3)

EPO Patents = 44 (Patent Applications = 52)

Average Co-Inventor Count = 5.1

ph-index = 28

Forward Citations = 2,981(Granted Patents)

Inventors with similar research interests:

Location History:

Bishop's Itchington, GB (2003)
Grove, Wantage, GB (2009)
Abingdon, Oxfordshire, GB (2010)
Oxfordshire, GB (2012)
Milton Park, GB (2012)
Grover Wantage, GB (2013)
Grove Wantage, GB (2005 - 2015)
Burford, GB (2015)
Abingdon, GB (2010 - 2020)
Grove, GB (2011 - 2020)
Wantage, GB (2003 - 2024)

Company Filing History:

139 out of 1,149

Vertex Pharmaceuticals, Inc.

1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2003-2025

Loading Chart...

140 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12187731 - Compounds useful as inhibitors of ATR kinase (2025-01-07),

2. 12084438 - GCN2 inhibitors and uses thereof (2024-09-10),

3. 11485739 - Compounds useful as inhibitors of ATR kinase (2022-11-01),

4. 11370798 - Compounds useful as inhibitors of ATR kinase (2022-06-28),

5. 11117900 - Compounds useful as inhibitors of ATR kinase (2021-09-14),

6. 10988477 - GCN2 inhibitors and uses thereof (2021-04-27),

7. 10961232 - Substituted pyrazines as ATR kinase inhibitors (2021-03-30),

8. 10822331 - Processes for preparing ATR inhibitors (2020-11-03),

9. 10815239 - Compounds useful as inhibitors of ATR kinase (2020-10-27),

10. 10800781 - Compounds useful as inhibitors of ATR kinase (2020-10-13),

11. 10793563 - GCN2 inhibitors and uses thereof (2020-10-06),

12. 10787452 - Compounds useful as inhibitors of ATR kinase (2020-09-29),

13. 10479784 - Substituted pyrazin-2-amines as inhibitors of ATR kinase (2019-11-19),

14. 10392391 - Compounds useful as inhibitors of ATR kinase (2019-08-27),

15. 10208027 - Processes for preparing ATR inhibitors (2019-02-19),

Title: Jean-Damien Charrier: A Prolific Inventor in the Field of ATR Protein Kinase Inhibitors

Introduction:

In the world of pharmaceutical research, inventors play a key role in developing new compounds and therapies for treating various diseases. One such inventor, Jean-Damien Charrier, hailing from Wantage, GB, has made remarkable contributions with his expertise in creating compounds useful as inhibitors of ATR protein kinase. With an impressive portfolio of 138 patents, Charrier's work has the potential to revolutionize the field of medicine. Let's explore some of his latest patents, career highlights, and collaborations.

Latest Patents:

Charrier's recent patents reflect his dedication to developing compounds that inhibit the ATR kinase protein, a crucial target in treating several diseases and disorders. His inventions encompass not only the compounds themselves but also their pharmaceutically acceptable compositions, methods of treatment, and processes for their preparation. Some of his latest patents include:

1. Compounds useful as inhibitors of ATR kinase: This patent details compounds with formula I-A or I-B, designed to inhibit the ATR protein kinase. These compounds hold great potential for the treatment of various diseases, disorders, and conditions.

2. Compounds useful as inhibitors of ATR kinase (in vitro applications): This patent explores the application of the compounds in in vitro studies, allowing for a better understanding of kinase-mediated biological and pathological phenomena. It also emphasizes the comparative evaluation of new kinase inhibitors.

Career Highlights:

Throughout his career, Charrier has had the opportunity to work with renowned companies in the pharmaceutical industry. Some of his notable career highlights include collaborations with Vertex Pharmaceuticals, Inc. and Merck Patent GmbH. The significance of his work is evident from the extensive number of patents he has amassed.

Collaborations:

Collaboration is often key to groundbreaking innovation, and Charrier has had the privilege of working alongside talented colleagues in his journey. Among his notable coworkers are Ronald Knegtel and Steven Durrant, whose combined expertise and contributions have further enriched their research.

Conclusion:

Jean-Damien Charrier's relentless pursuit of developing compounds as inhibitors of ATR protein kinase has positioned him as a leading inventor in the field of molecular medicine. With an impressive patent count of 138, Charrier's work showcases his commitment to advancing therapeutic possibilities for various diseases and disorders. Collaborations with industry giants and contributions to the understanding of kinase-mediated phenomena underline the significance of his research. As the world of pharmaceutical research continues to evolve, Charrier's innovative spirit promises a brighter future for medical breakthroughs.

Note: For more information about Jean-Damien Charrier, his patents, and related topics, you can explore our website idiyas.com, dedicated to innovations, inventions, and patents.

This text is generated by artificial intelligence and may not be accurate.